ESR1 and breast carcinoma: In this context, the low number of estrogen receptor‐positive (ER+) breast cancer cell lines presently available is disturbing, since 70–80% of patients with breast cancer harbor ER+ tumors and ER is the primary target of endocrine therapies in breast cancer (Pan et al, 2017).